Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
PF-3512676 · 2 trials · 6 indications
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | Patients will be treated with the same dosing regimen and schedule of PF-3512676 Injection with which they were treated at the end of the previous PF-3512676 Injection trial. Any proposed changes to their schedule/regimen will be at the discretion of the treating physician, following consultation with Coley. |
| Phase I: 0.08 mg/kg | EXPERIMENTAL | Escalating dose groups: 0.08 mg/kg PF-3512676 Injection |
| Phase I: 0.16 mg/kg | EXPERIMENTAL | Escalating dose groups: 0.16 mg/kg PF-3512676 Injection |
| Phase I: 0.24 mg/kg | EXPERIMENTAL | Escalating dose groups: 0.24 mg/kg PF-3512676 Injection |
| Phase I: 0.28 mg/kg | EXPERIMENTAL | Escalating dose groups: 0.28 mg/kg PF-3512676 Injection |
| Phase I: 0.32 mg/kg | EXPERIMENTAL | Escalating dose groups: 0.32 mg/kg PF-3512676 Injection |
| Phase I: 0.36 mg/kg | EXPERIMENTAL | Escalating dose groups: 0.36 mg/kg PF-3512676 Injection |
| Phase II: 10 mg | EXPERIMENTAL | Phase II: 10 mg flat dose (random assignment in Phase II) |
| Phase II: 25 mg | EXPERIMENTAL | Weekly subcutaneous injections of 25 mg PF-3512676. Treatment continues for a minimum of 8 weeks unless disease progression or unacceptable toxicity occurs, or a maximum of 24 weeks. |
| Name | Type | Description |
|---|---|---|
| PF-3512676 | DRUG | PF-3512676 IV at doses: 0.01mg/kg, 0.16mg/kg and 0.32mg/kg PF-3512676 Injection given by subcutaneous injection at doses: 0.04mg/kg, 0.16mg/kg, 0.20mg/kg, 0.28mg/kg, 0.32mg/kg, 6mg, 10mg, 40mg. |
Inclusion Criteria: Immediate (within 4 weeks) prior completion of a clinical trial of PF-3512676 Injection alone or in combination with other anti-neoplastic treatment for malignancy. Exclusion Criteria: The patient has received any anti-neoplastic therapy since completing a prior trial with PF-...
Top 20 of 51 competitors
PF-3512676 is an investigational small molecule being studied in oncology indications including non-small-cell lung carcinoma, melanoma, and cutaneous T-cell lymphoma. It has been evaluated in clinical trials for these conditions, though it remains in clinical development and is not approved.
PF-3512676 is a small molecule, but its specific molecular target has not been disclosed in available information. It is being studied for its potential effects in certain cancers, including non-small-cell lung carcinoma, melanoma, and cutaneous T-cell lymphoma.
PF-3512676 is being developed by Pfizer, Inc., a biopharmaceutical company traded on the New York Stock Exchange under the ticker symbol PFE. The drug is in Phase 1 clinical development for oncology indications.
PF-3512676 is in Phase 1 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities. Clinical trials have been completed, but the drug is not yet available for commercial use.
PF-3512676 has been studied in several completed clinical trials, including NCT00043368, NCT00043420, and NCT00321815. These trials evaluated the drug in patients with melanoma, breast neoplasms, renal cell carcinoma, cutaneous T-cell lymphoma, and non-small-cell lung carcinoma.
Yes, PF-3512676 is also known as CPG 7909. Clinical trials have used both names to refer to the same investigational drug, which is being studied for its potential use in treating certain types of cancer.